Cumulus Oncology
Developer of novel therapies designed for treating cancers. The company's lead candidate is an oral, selective, and preclinical Chk1 kinase inhibitor that helps in the activation of DNA repair, enabli...
Valuation
$0
Share Price
N/A
Total Raised
$69.1M
Last Round
N/A